biotech stocks sold hard friday wall street blamed letter several house democrats asking gilead sciences justify price hepatitis c blockbuster sovaldi
letter dated thursday signed reps henry waxman frank pallone diana degete ranking members committee energy commerce called sovaldi breakthrough hcv treatment expressed concern treatment cure patients cannot afford
due sovaldis 8400 price tag letter went say colorados pennsylvanias medicaid programs already announced theyre funding sovaldi sickest patients californias still figuring reimbursement policies letter also noted pharmacy benefit manager express scripts esrx encouraging doctors networks delay prescribing sovaldi
meanwhile hepatitis c disease found disproportionately among poor result lawmakers told gilead provide explanation pricing april 3
health insurer wellpoint wlp chimed friday concerns new hepatitis c drug costs said executive ken goulet
gileads gild fell nearly 5 7207 3month closing low biotechs selling expensive drugs fell even harder perhaps fears larger change national mood drug pricing
alexion pharmaceuticals alxn whose sole drug soliris goes upward 40000 year tumbled 8 vertex pharmaceuticals vrtx also sells expensive hepatitis c drug called incivek retreated 5
abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rallied friday closed fraction
like gilead caught cold rest market caught pneumonia said tom vandeventer portfolio manager tocqueville opportunity fund
analysts part advised staying calm michael yee rbc capital markets wrote email clients friday pricing discussions could generate headline concern view underscores drug going huge theyre curing patients improving society hcv important public health issue like hiv validates significance market
deutsche bank analyst robyn karnauskas wrote client note shed spoken gilead officials already making case sovaldi actually bargain
liver transplant related hcv costs 25000 another 5000 year meds person reject liver wrote gilead copay programs place outofpocket cost low 5
isi group analyst mark schoenebaum pointed sovaldi compares favorably older hepatitis c drugs especially vertexs incivek goes 10000 year sovaldis cure rate also much higher inciveks cost per cure even better said webinar friday
schoenebaum also queried terry haines longtime washington lawyer lobbyist served senior republican counsel congres sional committee sent letter haines responded government actually little power address drug prices view waxman et al hope accomplish public shaming unlike one waxman delivered tobacco industry years ago
letter bank shot gets things going goal getting gilead significantly lower price sovaldi haines wrote
move could politically popular added discontent high price sovaldi new drugs general swelling payers general public time aids healthcare foundation large nonprofit history criticizing gilead hiv drug pricing recently turned fire sovaldi
gileads latest display outoftouch greed comes heels companys january pricing new hepatitis c treatment sovaldi sofosbuvir 100 per pill 1100 gileads expensive aids drug stribild ahf said feb 4 press release
played biotech stocks hit lull last weeks bull run seen since 1990s leading fear party may vandeventer says biotechs high beta group probably correction points drug prices political football since early 1990s
shouldnt completely unexpected kinds issues come fore periodically said part investing health care
